Condition: Cervical Intraepithelial Neoplasia · Squamous Intraepithelial Lesions of the Cervix · Uterine Cervical Dysplasia · Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Conservative management of high-grade squamous intraepithelial lesions (HSILs) seems safe and justified in young women (\<30 years), but evidence is insufficient on whether it is also advisable for older women. This study will be conducted to analyze spontaneous HSIL regression rates in women of reproductive age and establish whether conservative HSIL management could be safely recommended to women of childbearing potential, irrespective of age. This is a single-center prospective observational study that will include consecutive women of reproductive age, referred to a tertiary hospital due to HSIL between March 2021 and December 2025, who prefer conservative management rather than immediate cervical conization. All patients will be followed-up regularly with colposcopy, cytology, human papillomavirus (HPV) testing and biopsies. In case their lesions progress or HSIL persists after 24 months of follow-up, conization will be indicated. Rates of spontaneous regression or resolution, as well as progression rates, will be assessed. Furthermore, the association between potential predictive factors and HSIL resolution will be analyzed.
This description comes directly from the study's public registry record.
Natalia Teixeira, MD, Ph.D. · +34604311873 · nteixeira@santpau.cat
Nerea Nerea, MD · +34935537041 · nluqui@santpau.cat
Always discuss trial participation with your own doctor first.
| Hospital de la Santa Creu i Sant Pau | Barcelona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04783805